ReviewGene therapy2023
Insidious Insights: Implications of viral vector engineering for pathogen enhancement.
Review in Gene therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- A novel gene delivery platform based on a commensal human anellovirus demonstrates transduction in multiple tissue types.Molecular therapy. Methods & clinical development · 2025Article
- Dual-Use Research and Publication Policies: A Comparison of Journals in Life Sciences and Artificial Intelligence.Applied biosafety : journal of the American Biological Safety Association · 2025Article
- Balancing Innovation and Safety: Frameworks and Considerations for the Governance of Dual-Use Research of Concern and Potential Pandemic Pathogens.Applied biosafety : journal of the American Biological Safety Association · 2025Review
- Awareness of the dual-use dilemma in scientific research: reflections and challenges to Latin America.Frontiers in bioengineering and biotechnology · 2025Article
- Review
- AI and biosecurity: The need for governance.Science (New York, N.Y.) · 2024Article
- Application of Optogenetics in Neurodegenerative Diseases.Cellular and molecular neurobiology · 2024Review
- Peptosome: A New Efficient Transfection Tool as an Alternative to Liposome.International journal of molecular sciences · 2024Article
- Bridging biosafety and biosecurity gaps: DURC and ePPP policy insights from U.S. institutions.Frontiers in bioengineering and biotechnology · 2024Article
- Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation.Molecular cancer · 2023Review
- Biosecurity in an age of open science.PLoS biology · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Optimizing viral vectors and their properties will be important for improving the effectiveness and safety of clinical gene therapy. However, such research may generate dual-use insights relevant to the enhancement of pandemic pathogens. In particular, reliable and generalizable methods of immune evasion could increase viral fitness sufficient to cause a new pandemic. High potential for misuse is associated with (1) the development of universal genetic elements for immune modulation, (2) specific insights on capsid engineering for antibody evasion applicable to viruses with pandemic potential, and (3) the development of computational methods to inform capsid engineering. These risks may be mitigated by prioritizing non-viral delivery systems, pharmacological immune modulation methods, non-genetic vector surface modifications, and engineering methods specific to AAV and other viruses incapable of unassisted human-to-human transmission. We recommend that computational vector engineering and the publication of associated code and data be limited to AAV until a technical solution for preventing malicious access to viral engineering tools has been established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.